Pfizer applies for EUA for variant-tailored booster; unveils new efficacy data for youngest children
Pfizer yesterday announced its application for an emergency use authorization for a COVID-19 vaccine booster that is designed to protect against the SARS-CoV-2 omicron variant. The booster is meant for the 12 and older age group. Pfizer’s application includes clinical data for bivalent Omicron BA.1-adapted vaccine and pre-clinical and manufacturing data from the companies’ bivalent Omicron BA.4/BA.5-adapted vaccine.
Pfizer today also released updated data on the efficacy of its COVID-19 vaccine when used for children between the ages of six months and four years old, indicating a 70% effectiveness across existing SARS-CoV-2 variants.
Related News Articles
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…